24/7 Market News Snapshot 09 June, 2025 – PolyPid Ltd. Ordinary Shares (NASDAQ:PYPD)

June 9, 2025

DENVER, Colo., 09 June, 2025 (www.247marketnews.com) – (NASDAQ:PYPD) are discussed in this article.
PolyPid Ltd. has seen a remarkable upswing in its stock price, trading at $3.891 in the pre-market session, which marks an increase of 18.99% from the previous closing value of $3.270. This surge can be attributed to heightened investor interest, evidenced by a trading volume of 16.85 million shares. This trend may signal positive market sentiment regarding the company’s recent advancements. Investors are advised to monitor key technical indicators, such as moving averages and the relative strength index (RSI), alongside support and resistance levels for informed decision-making.

Simultaneously, PolyPid has announced on the success of its SHIELD II Phase 3 trial for D-PLEX100, an innovative treatment aimed at preventing surgical site infections (SSIs) in patients undergoing abdominal colorectal procedures. The double-blind study, which encompassed 798 participants, delivered significant statistical improvements across primary and secondary endpoints, including a 38% reduction in the primary composite endpoint and a notable 58% decrease in SSI rates, dropping from 9.5% to 3.8% compared to standard care practices.

D-PLEX100’s efficacy addresses the substantial healthcare challenge presented by SSIs, which incur approximately $10 billion in annual costs. In light of these compelling results, PolyPid is preparing for a pre-New Drug Application (NDA) meeting with the FDA scheduled for late 2025, with plans for NDA submission by early 2026.

Dikla Czaczkes Akselbrad, the CEO of PolyPid, extended her appreciation to all stakeholders involved in the trial, underscoring the transformative potential of D-PLEX100 in surgical settings. Dalit Hazan, Deputy CEO, highlighted the excitement surrounding forthcoming presentations at major medical conferences, aiming to engage the surgical community about D-PLEX100’s impactful role in enhancing patient care and infection prevention strategies.

Related news for (PYPD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.